John Cogswell

Company: TriStar Technology Group LLC

Job title: Senior Group Consultant, Clinical Biomarkers

Seminars:

Prevalence Of Potential Antibody Drug Conjugate (ADC) Targets With PD-L1 In Breast Cancer And Lung Cancer Patients With Clinical Response Information 1:00 pm

Breast and Lung cancer are important diseases for antibody drug conjugate (ADC) therapeutic development with several approved in both diseases Tristar ran approved IHC assays for HER2 and PD-L1 and optimized IHC assays for TROP2, NECTIN-4, B7-H3, and B7-H4 on serial slides from tissue microarrays for breast (hormone receptor positive) and non-small cell lung cancer…Read more

day: Conference Day One